1

Innate lymphoid cells and disease tolerance in SARS-CoV-2 infection

Noah J. Silverstein[1,2,3*], Yetao Wang[1,3*], Zachary Manickas-Hill[3,4], Claudia Carbone[1], Ann Dauphin[1], Brittany P. Boribong[5,6,7], Maggie Loiselle[5], Jameson Davis[5], Maureen M. Leonard[5,6,7], Leticia Kuri-Cervantes[8,9], MGH COVID-19 Collection & Processing Team, Nuala J. Meyer[10], Michael R. Betts[8,9], Jonathan Z. Li[3,11], Bruce Walker[3,4,12,13], Xu G. Yu[3,4,11], Lael M. Yonker[5,6,7], Jeremy Luban[1,3,14,15]

[1]Program in Molecular Medicine, University of Massachusetts Medical School, Worcester, MA 01605, USA
[2]Medical Scientist Training Program, University of Massachusetts Medical School, Worcester, MA 01605, USA
[3]Massachusetts Consortium on Pathogen Readiness, Boston, MA, 02115
[4]Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA
[5]Massachusetts General Hospital, Mucosal Immunology and Biology Research Center, Boston, MA, USA
[6]Massachusetts General Hospital, Department of Pediatrics, Boston, MA, USA
[7]Harvard Medical School, Boston, MA, USA
[8]Department of Microbiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA
[9]Institute for Immunology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA.
[10]Division of Pulmonary and Critical Care Medicine, Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
[11]Department of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA
[12]Howard Hughes Medical Institute, Chevy Chase, MD 20815, USA
[13]Department of Biology and Institute of Medical Engineering and Science, Massachusetts Institute of Technology, Cambridge, MA
[14]Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Medical School, Worcester, MA 01605, USA
[15]Broad Institute of Harvard and MIT, 75 Ames Street, Cambridge, MA 02142, USA

*These authors contributed equally

Correspondence: yetao.wang@umassmed.edu (Y.W.); jeremy.luban@umassmed.edu (J.L.)

Abstract:

Risk of severe COVID-19 increases with age, is greater in males, and is associated with lymphopenia, but not with higher burden of SARS-CoV-2. It is unknown whether effects of age and sex on abundance of specific lymphoid subsets explain these correlations. This study found that the abundance of innate lymphoid cells (ILCs) decreases more than 7-fold over the human lifespan — T cell subsets decrease less than 2-fold — and is lower in males than in females. After accounting for effects of age and sex, ILCs, but not T cells, were lower in adults hospitalized with COVID-19, independent of lymphopenia. Among SARS-CoV-2-infected adults, the abundance of ILCs, but not of T cells, correlated inversely with odds and duration of hospitalization, and with severity of inflammation. ILCs were also uniquely decreased in pediatric COVID-19 and the numbers of these cells did not recover during follow-up. In contrast, children with MIS-C had depletion of both ILCs and T cells, and both cell types increased during follow-up. In both pediatric COVID-19 and MIS-C, ILC abundance correlated inversely with inflammation. Blood ILC mRNA and phenotype tracked closely with ILCs from lung. Importantly, blood ILCs produced amphiregulin, a protein implicated in disease tolerance and tissue homeostasis, and the percentage of amphiregulin-producing ILCs was higher in females than in males. These results suggest that, by promoting disease tolerance, homeostatic ILCs decrease morbidity and mortality associated with SARS-CoV-2 infection, and that lower ILC abundance accounts for increased COVID-19 severity with age and in males.

INTRODUCTION

The risk of severe COVID-19 and death in people infected with SARS-CoV-2 increases with age and is greater in men than in women (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). These trends have been observed in people infected with SARS-CoV (Chen and Subbarao, 2007; Donnelly et al., 2003; Karlberg, 2004), or with MERS-CoV (Alghamdi et al., 2014), and in laboratory animals challenged with SARS-CoV or SARS-CoV-2 (Channappanavar et al., 2017; Leist et al., 2020). Yet, the mechanisms underlying these effects of age and sex on COVID-19 morbidity and mortality remain poorly understood.

The composition and function of the human immune system changes with age and exhibits sexual dimorphism (Darboe et al., 2020; Klein and Flanagan, 2016; Márquez et al., 2020; Patin et al., 2018; Solana et al., 2012), with consequences for survival of infection, response to vaccination, and susceptibility to autoimmune disease (Flanagan et al., 2017; Giefing-Kröll et al., 2015; Márquez et al., 2020; Mauvais-Jarvis, 2020; Patin et al., 2018; Piasecka et al., 2018). Better understanding of these effects might provide clues as to why the clinical outcome of SARS-CoV-2 infection is so variable, ranging from asymptomatic to lethal (Cevik et al., 2021; He et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Richardson et al., 2020; Yang et al., 2021).

Survival after infection with a pathogenic virus such as SARS-CoV-2 requires not only that the immune system control and eliminate the pathogen, but that disease tolerance mechanisms limit tissue damage caused by the pathogen or by host inflammatory responses (Ayres, 2020a; McCarville and Ayres, 2018; Medzhitov et al.,

2012; Schneider and Ayres, 2008). Research with animal models has demonstrated that

genetic and environmental factors can promote host fitness without directly inhibiting

pathogen replication (Ayres, 2020a; Cumnock et al., 2018; Jhaveri et al., 2007; McCarville

and Ayres, 2018; Medzhitov et al., 2012; Råberg et al., 2007; Sanchez et al., 2018;

Schneider and Ayres, 2008; Wang et al., 2016). Although in most cases the underlying

mechanism is unknown, some of these models suggest that subsets of innate lymphoid

cells (ILCs) contribute to disease tolerance (Artis and Spits, 2015; Branzk et al., 2018;

Califano et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et

al., 2015, 2011).

ILCs lack clonotypic antigen receptors but overlap developmentally and

functionally with T cells. Based on expression of characteristic transcription factors and

specific inducible cytokines, ILCs are classified into ILC1, ILC2, and ILC3 subsets that

are analogous to T_H1, T_H2, and T_H17 cells respectively (Artis and Spits, 2015; Cherrier et

al., 2018; Vivier et al., 2018; Yudanin et al., 2019). Additionally, some ILC subsets

produce the epidermal growth factor family member amphiregulin (AREG) that maintains

the integrity of epithelial barriers in the lung and intestine (Branzk et al., 2018; Jamieson

et al., 2013; Monticelli et al., 2015, 2011), and promotes tissue repair (Artis and Spits,

2015; Cherrier et al., 2018; Klose and Artis, 2016; Rak et al., 2016). In models of influenza

infection in mice, homeostatic ILCs and exogenous AREG promote lung epithelial

integrity, decrease disease severity, and increase survival, without decreasing pathogen

burden (Califano et al., 2018; Jamieson et al., 2013; Monticelli et al., 2011).

Little is known about disease tolerance in the context of human infectious

diseases. Interestingly, SARS-CoV-2 viral load does not reliably discriminate

symptomatic from asymptomatic infection (Cevik et al., 2021; Jones et al., 2021; Lee et

al., 2020; Lennon et al., 2021; Ra et al., 2021; Yang et al., 2021). This discrepancy

between SARS-CoV-2 viral load and the severity of COVID-19 is especially pronounced

in children, who rarely have severe COVID-19 (Charles Bailey et al., 2020; Li et al., 2020;

Lu et al., 2020; Poline et al., 2020), though viral load may be comparable to that in adults

with severe COVID-19 (Heald-Sargent et al., 2020; LoTempio et al., 2021; Yonker et al.,

2020). These observations suggest that age-dependent, disease tolerance mechanisms

influence the severity of COVID-19. In mice, homeostatic ILCs decrease in abundance in

the lung with increasing age, and lose their ability to maintain disease tolerance during

influenza infection (D'Souza et al., 2019). Although the distribution of ILCs within human

tissues differs from mice and is heterogeneous among individuals (Yudanin et al., 2019),

human ILCs share many features with those in mice (Vivier et al., 2018) and therefore

likely perform similar roles in maintaining tissue homeostasis and disease tolerance.

ILCs in peripheral blood have been reported to be depleted in individuals with

severe COVID-19 (García et al., 2020; Kuri-Cervantes et al., 2020), but it is difficult to

determine the extent to which ILCs are decreased independently from the overall

lymphopenia associated with COVID-19 (Chen et al., 2020; Huang et al., 2020; Huang

and Pranata, 2020; Zhang et al., 2020; Zhao et al., 2020), or from the reported decreases

in other blood lymphoid cell populations (Kuri-Cervantes et al., 2020; Lucas et al., 2020;

Mathew et al., 2020; Mudd et al., 2020; Zheng et al., 2020). In addition, assessment of

lymphoid cell abundance, in the context of a disease for which age and sex are risk factors

for severity, is confounded by programmed differences in lymphocyte abundance with

age and sex (Márquez et al., 2020; Patin et al., 2018). The goal of this study was to

determine whether the abundance of any blood lymphoid cell population was altered in

COVID-19, independent of age, sex, and global lymphopenia, and whether abundance of

any lymphoid cell population correlated with clinical outcome in SARS-CoV-2 infection.

RESULTS

Characteristics of adult blood donors hospitalized for COVID-19, treated for COVID-19 as outpatients, or SARS-CoV-2-uninfected controls

The first group of blood donors in this study included SARS-CoV-2-infected adults hospitalized for severe COVID-19 (N = 40), among whom 33 (82.5%) were admitted to the ICU, 32 (80%) required intubation with mechanical ventilation, and 7 (17.5%) died (Table 1). This group had a mean age of 57.6 (range 24 to 83) and 60% were males. The second group consisted of adults infected with SARS-CoV-2 who were treated for COVID-19 as outpatients (N=51). This group had a mean age of 36.8 years (range 23-77) and was 25.5% male (Table 1). Differences between these two SARS-CoV-2-infected groups, in terms of median age ($p = 5.2 \times 10^{-8}$) and sex ratio ($p = 3.7 \times 10^{-3}$) (Fig. 1), were consistent with the established greater risk of severe COVID-19 in older individuals and in males (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). Available information concerning ethnicity and race of the blood donors was insufficient for statistical comparisons among the groups (Supplementary Table S1). Finally, 86 adults who donated blood prior to the SARS-CoV-2 outbreak, or who were screened at a blood donation center, were included as controls for SARS-CoV-2 infection. The age of this group spanned the range of the two groups of SARS-CoV-2-infected people (mean age 50.9; range 23 to 79), and the percentage of males (55.8%) was similar to that of the group hospitalized for COVID-19 (Table 1 and Fig. 1).

Table 1: Demographic and Clinical Characteristics of Adult Blood Donor Groups

Characteristic	Healthy Control N=86	Hospitalized N=40	Outpatient N=51
Mean age (range) - years	50.9 (23-79)	57.6 (24-83)	36.8 (23-77)
Sex – number (%)			
Male	48 (55.8)	24 (60)	13 (25.5)
Female	38 (44.2)	16 (40)	38 (74.5)
Mean symptom duration at sample collection (range) – days		21.8 (5-66)	26.9 (1-61)
ICU admission – number (%)		33 (82.5)	
Intubation with mechanical ventilation – number (%)		32 (80)	
Deaths – number (%)		7 (17.5)	
Mean time hospitalized (range) – days		34.2 (4-87)	
Max lab value – mean (range)			
CRP – mg/L		228.6 (6.5-539.5)	
ESR – mm/h		89.0 (15-146)	
D-dimer – (ng/mL)		5700 (351-11923)	

Characteristics of pediatric blood donors with COVID-19, MIS-C, or SARS-CoV-2-uninfected controls

Children are less likely than adults to have severe disease when infected with SARS-CoV-2 despite having viral loads as high as adults (Charles Bailey et al., 2020; Heald-Sargent et al., 2020; Li et al., 2020; LoTempio et al., 2021; Lu et al., 2020; Poline et al., 2020; Yonker et al., 2020). Rarely, after SARS-CoV-2 clearance from the upper airways, children can develop severe Multisystem Inflammatory Syndrome in Children (MIS-C), a life-threatening condition distinct from COVID-19 that presents with high fevers and multiorgan injury, often including coronary aneurysms, ventricular failure, or myocarditis (Cheung et al., 2020; Feldstein et al., 2021, 2020; Licciardi et al., 2020; Riphagen et al., 2020; Verdoni et al., 2020; Whittaker et al., 2020).

The first cohort of pediatric blood donors in this study consisted of patients with COVID-19 who were treated in hospital (N=11) or as outpatients (N=8). The second cohort of pediatric blood donors was patients hospitalized for MIS-C (N=11). Seventeen SARS-CoV-2-uninfected pediatric blood donors constituted a control group. No significant differences in age or percentage of males were detected among the pediatric COVID-19, MIS-C, or pediatric control groups (Supplementary Table S2 and Fig. 1).

Fig. 1. Age and sex of control and SARS-CoV-2-infected blood donors

Age of the subjects is shown, along with the number of subjects and fraction male in each

group, for adult (left) and pediatric (right) cohorts, as indicated. P-values are from

pairwise, two-sided, Wilcoxon rank-sum test for ages and Fisher's exact test for fraction

male, with Bonferroni correction for multiple comparisons. Adjusted P-values < 0.05 are

shown.

Blood ILC abundance decreases exponentially across the lifespan and is sexually dimorphic

Lymphoid cell abundance in peripheral blood changes with age and is sexually dimorphic (Márquez et al., 2020; Patin et al., 2018). Previous studies reporting the effect of COVID-19 on the abundance of blood lymphoid cell subsets have not fully accounted for the association of age and sex with COVID-19 severity. To isolate the effect of COVID-19 on cell abundance from effects of age and sex, PBMCs were collected from 103 SARS-CoV-2-negative blood donors distributed from 2 to 79 years of age, with a nearly equal ratio of males to females. Abundance of lymphoid cell types was plotted by 20-year age groups (Fig. 2A), as well as by sex (Fig. 2B). Lymphoid cell types assessed here included CD4$^+$ T cells, CD8$^+$ T cells, ILCs, and FcγRIII (CD16)-positive NK cells. Like CD8$^+$ T cells, NK cells kill virus-infected cells using perforin and granzyme (Artis and Spits, 2015; Cherrier et al., 2018). Additionally, by binding virus-specific immunoglobulins that target virus-infected cells for antibody-dependent cellular cytotoxicity, CD16$^+$ NK cells link innate and acquired immunity (Anegon et al., 1988).

All cell types examined here were affected by age, but ILCs were the only subset with significant differences among all age groups, falling approximately 2-fold in median abundance every 20 years, with a greater than 7-fold decrease from the youngest to oldest age groups ($p = 1.64 \times 10^{-11}$) (Fig. 2A). This magnitude of decrease was unique to ILCs and corresponded inversely with the exponential increase in COVID-19 mortality with age (O'Driscoll et al., 2020) (Fig. 2C). In addition, both ILCs and CD4$^+$ T cells were less abundant in males (Fig. 2B). These findings highlight the importance of accounting for effects of age and sex when assessing group differences in lymphoid cell abundance,

215   particularly in the context of a disease such as COVID-19 that disproportionately affects

216   older males (O'Driscoll et al., 2020).

Fig. 2. Blood ILC abundance decreases exponentially across the lifespan mirroring

the mortality rate from SARS-CoV-2 infection

(**A-B**) Log2 abundance per million lymphocytes of the indicated lymphoid cell populations

in combined pediatric and adult control data plotted by 20-year bin or by sex, as indicated.

Each dot represents an individual blood donor. Boxplots represent the distribution of the

data with the center line drawn through the median with the upper and lower bounds of

the box at the 75th and 25th percentiles respectively. The upper and lower whiskers

extend to the largest or smallest values within 1.5 x the interquartile range (IQR). P-values

are from two-sided, Wilcoxon rank-sum tests with Bonferroni correction for multiple

comparisons. Adjusted P-values < 0.05 are shown.

(**C**) Case numbers and mortality rate within the indicated age ranges for cases reported

in the United States between Jan 1, 2020, and June 6, 2021.

Adults hospitalized with COVID-19 have fewer total lymphocytes even after accounting for effects of age and sex

Severe COVID-19 is associated with lymphopenia (Chen et al., 2020; Huang et al., 2020; Huang and Pranata, 2020; Zhang et al., 2020; Zhao et al., 2020) but it remains unclear if this effect is due to reduction in particular lymphoid cell subpopulations, or whether this effect is explained by the more advanced age and higher proportion of males among people with severe COVID-19. As a first step to assess the specificity of lymphocyte depletion, the effect of COVID-19 on total lymphocyte abundance was addressed with multiple linear regression. After accounting for effects of age and sex, individuals hospitalized with severe COVID-19 had 1.33-fold (95%CI: 1.49–1.19; $p = 1.22 \times 10^{-6}$) fewer total lymphocytes among PBMCs than did controls (Supplementary Table S3). Lymphocyte abundance in people infected with SARS-CoV-2 who were treated as outpatients was not different from controls (Supplementary Table S3). In addition, total lymphocytes decreased with age and were less abundant in males (Supplementary Table S3). Subsequent analyses of lymphoid cell subsets took into account the depletion in total lymphocytes associated with COVID-19 by assessing lymphoid subsets as a fraction of total lymphocytes.

After accounting for age and sex, only innate lymphoid cells are depleted in severe COVID-19

To determine whether there were independent associations between lymphoid cell subsets and COVID-19, multiple linear regression was performed on the abundance of lymphoid cell subsets, with age, sex, and group (control, hospitalized, and outpatient) as independent variables. Across all three groups of adult blood donors, CD4$^+$ T cells, CD8$^+$

267   T cells, and ILCs decreased with age, while CD16[+] NK cells increased with age, and both

268   CD4[+] T cells and ILCs were less abundant in males (Table 2 and Fig. 3A).

Table 2: Change in Cell Abundance Due to Age, Sex, and COVID-19 Severity

Fold difference (log2) [±95%CI]

	CD4[+] T[a]	ILC[a]	CD8[+] T[a]	CD16[+] NK[a]
Age	-0.012***	-0.043***	-0.009*	0.021***
	[-0.018, -0.005]	[-0.053, -0.033]	[-0.016, -0.002]	[0.010, 0.032]
Male	-0.409***	-0.334*	-0.177	0.184
	[-0.618, -0.201]	[-0.659, -0.010]	[-0.406, 0.051]	[-0.169, 0.538]
Hospitalized	0.168	-0.835***	0.227	-1.205***
	[-0.084, 0.421]	[-1.228, -0.441]	[-0.050, 0.503]	[-1.633, -0.778]
Outpatient	0.332*	-0.088	-0.023	-0.522*
	[0.082, 0.581]	[-0.478, 0.302]	[-0.298, 0.253]	[-0.948, -0.095]
R^2	0.275	0.478	0.070	0.232

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
[a] per 10^6 lymphocytes

When effects of age and sex were held constant, adults hospitalized with COVID-

19 had 1.78-fold fewer ILCs (95%CI: 2.34–1.36; $p = 4.55 \times 10^{-5}$) and 2.31-fold fewer

CD16[+] natural killer (NK) cells (95%CI: 3.1–1.71; $p = 1.04 \times 10^{-7}$), as compared to controls

(Table 2 and Fig. 3B). Similar effects were also seen with ILC precursors (ILCP)

(Supplementary Fig. S1). Neither CD4[+] T cells nor CD8[+] T cells were depleted further

than expected for age and sex (Table 2 and Fig. 3B). As compared with controls, SARS-

CoV-2-infected adults with less severe COVID-19 who were treated as outpatients had

no reduction in ILCs, but 1.44-fold fewer CD16$^+$ NK cells (95%CI: 1.93–1.07; p = 0.018),

and 1.26-fold higher CD4$^+$ T cells (95%CI: 1.06–1.5; p = 9.59 x 10^{-3}) (Table 2 and Fig.

3B). As these analyses were performed on lymphoid cell abundance normalized to total

lymphocyte number, it is possible that T cells were not lower in patients hospitalized with

COVID-19 because the amount of depletion was not in excess of the change in total

lymphocytes. However, the cell-type specific results remained unchanged even when the

analyses were repeated using the less stringent threshold of normalizing to total PBMC

number (Supplementary Table S4).

When data from an independent, previously published cohort (Kuri-Cervantes et

al., 2020) were analyzed to account for total lymphocyte abundance, age, and sex, people

hospitalized with acute respiratory distress syndrome due to COVID-19, had 1.7-fold

fewer ILCs (95%CI: 2.38–1.22; p = 0.002) than controls (Supplementary Fig. S2). Also

consistent with the main adult cohort studied here, ILC abundance was not significantly

reduced in the group of patients with less severe disease (Supplementary Fig. S2).

Fig. 3. Innate lymphoid cells are depleted in adults hospitalized with COVID-19 and

ILC abundance correlates inversely with disease severity.

(**A**) Effect of age (X-axis) on log2 abundance per million total lymphocytes of the indicated

lymphoid cell populations (Y-axis), as determined by the regression analysis in Table 2.

Each dot represents an individual blood donor, with yellow for female and blue for male.

Shading represents the 95%CI. P-values are from the regression analysis for

comparisons to the control group.

(**B**) Log2 abundance per million lymphocytes of the indicated lymphoid cell populations,

shown as estimated marginal means with 95%CI, generated from the multiple linear

regressions in Table 2, and averaged across age and sex. P-values represent pairwise

comparisons on the estimated marginal means, adjusted for multiple comparisons with

the Tukey method. Adjusted P-values < 0.05 are shown.

(**C**) Association of the indicated clinical parameters with log2 abundance of ILCs per

million lymphoid cells. Regression lines are from simplified multiple regression models to

permit visualization on a two-dimensional plane. Shading represents the 95%CI. Results

of the full models accounting for effects of both age and sex, are reported in Table 4 and

the text.

Odds of hospitalization in adults infected with SARS-CoV-2 increases with decreasing number of ILCs

Multiple logistic regression was used next to determine whether differences in abundance of any lymphoid cell subset was associated with odds of hospitalization in people infected with SARS-CoV-2. The adjusted odds ratio was calculated using lymphoid cell subset abundance, age, sex, and duration of symptoms at the time of blood draw, each as independent variables. Abundance of ILCs, but not of CD16[+] NK cells, CD4[+] T cells, or CD8[+] T cells was associated with odds of hospitalization: the odds ratio for hospitalization, adjusted for age, sex, and symptom duration, was 0.413 (95%CI: 0.197–0.724; p = 0.00691), an increase of 58.7% for each 2-fold decrease in ILC abundance (Table 3).

Table 3: Odds of Hospitalization[a]

Cell count[b]	Odds Ratio[c]	95% Confidence Interval	P-Value
CD4[+] T	0.501	0.184–1.07	0.106
ILC	0.413	0.197–0.724	0.007
CD8[+] T	1.22	0.635–2.64	0.579
CD16[+] NK	0.814	0.53–1.21	0.309

[a]Adjusted for age, sex, and symptom duration at time of sample collection
[b]per 10^6 lymphocytes
[c]per 2-fold increase in cell population abundance

Duration of hospital stay in adults with COVID-19 increases with decreasing ILC abundance

The relationship between lymphoid cell abundance and duration of hospitalization was assessed to determine whether the association between ILC abundance and COVID-19

severity extended to clinical outcomes within the hospitalized adults. This relationship

was assessed with multiple linear regression, including age, sex, and cell abundance as

independent variables. Holding age and sex constant, abundance of ILCs, but not of

CD16[+] NK cells, CD4[+] T cells, or CD8[+] T cells, was associated with length of time in the

hospital: each two-fold decrease in ILC abundance was associated with a 9.38 day

increase in duration of hospital stay (95% CI: 15.76–3.01; p = 0.0054) (Fig. 3C and Table

4).

Table 4: Association of cell type abundance with time in hospital and laboratory values[a]

Cell count[b]	Days hospitalized	CRP (mg/L)[c]	ESR (mm/h)[c]	D-dimer (ng/mL)[c]
CD4[+] T	-10.843	-3.335	-2.674	-1868.847*
	[-22.511, 0.825]	[-56.162, 49.492]	[-23.840, 18.492]	[-3375.630, -362.063]
ILC	-9.381**	-46.288***	-11.035*	-1098.515*
	[-15.755, -3.008]	[-71.337, -21.238]	[-21.936, -0.134]	[-1932.842, -264.188]
CD8[+] T	3.366	32.247	15.317	486.192
	[-8.992, 15.724]	[-16.509, 81.003]	[-4.127, 34.761]	[-1049.836, 2022.221]
CD16[+] NK	-4.775	-14.619	-5.159	-404.873
	[-11.251, 1.701]	[-44.011, 14.774]	[-16.809, 6.491]	[-1316.261, 506.516]

* p < 0.05, ** p < 0.01, *** p < 0.001
[a]coefficients are for each two-fold increase in cell population abundance, adjusted for age and sex [±95%CI]
[b]per 10^6 lymphoid cells
[c]Maximum lab value recorded during course of hospitalization

ILC abundance correlates inversely with markers of inflammation in adults

hospitalized with COVID-19

To further characterize the extent to which lymphoid cell abundance predicted COVID-19

severity, multiple regression with age, sex, and cell abundance, as independent variables,

was performed on peak blood levels of inflammation markers indicative of COVID-19

severity: C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), and the

fibrin degradation product D-dimer (Gallo Marin et al., 2020; Gupta et al., 2021; Luo et

al., 2020; Zhang et al., 2020; Zhou et al., 2020). Holding age and sex constant, each two-

fold decrease in ILC, but not in CD16$^+$ NK cell, CD4$^+$ T cell, or CD8$^+$ T cell abundance,

was associated with a 46.29 mg/L increase in blood CRP (95% CI: 71.34–21.24; p = 6.25

x 10^{-4}) and 11.04 mm/h increase in ESR (95% CI: 21.94–0.13; p = 0.047) (Fig. 3C and

Table 4). Abundance of both ILCs and CD4$^+$ T cells was associated with blood levels of

D-dimer, with each two-fold decrease in cell abundance associated with an increase in

D-dimer by 1098.52 ng/mL (95% CI: 1932.84–264.19; p = 0.011) and 1868.85 ng/mL

(95% CI: 3375.63–362.06; p = 0.016), respectively (Table 4).

ILCs are depleted in children and young adults with COVID-19 or MIS-C

Given the decline in ILC abundance with age (Fig.s 2A and 3A, and Table 2), and the

inverse relationship between ILC abundance and disease severity in adults (Fig. 3C,

Table 3, and Table 4), it was hypothesized that children as a group have less severe

COVID-19 because ILC abundance is higher at younger ages, and that pediatric cases

with symptomatic SARS-CoV-2 infection, or with MIS-C, are accompanied by significantly

lower numbers of ILCs. To test these hypotheses, the abundance of lymphoid cell subsets

in pediatric COVID-19 or MIS-C was compared with that from pediatric controls, using

multiple linear regression with age, sex, and group as independent variables. Consistent

with the findings in adults, blood ILCs in the pediatric cohort decreased with age (Table 5

and Fig. 4A), demonstrating that the decrease in ILC abundance across the lifespan is

already evident within the first two decades of life. In contrast, significant change over this

age range was not detected in the abundance of CD4$^+$ T cells, CD8$^+$ T cells, or CD16$^+$

NK cells (Table 5 and Fig 4A).

Among pediatric patients with COVID-19, no difference in abundance of the

lymphoid cell subsets was associated with hospitalization (Supplementary Table S5), so

all pediatric patients treated for COVID-19 were analyzed as a single group. After

accounting for effects of age and sex, pediatric patients with COVID-19 had 1.69-fold

fewer ILCs (95%CI: 2.73–1.04; p = 0.034) than controls (Fig 4A and Table 5). Neither

CD4$^+$ T cells, CD8$^+$ T cells, nor CD16$^+$ NK cells were depleted in pediatric COVID-19

patients (Fig 4A and Table 5).

As with pediatric COVID-19, ILCs were also lower in MIS-C, with 2.14-fold fewer

ILCs (95%CI: 3.69–1.24; p = 0.007) than controls (Fig. 4A and Table 5). However, unlike

pediatric COVID-19, individuals with MIS-C had reduced numbers of T cells as compared

with pediatric controls, with 1.6-fold fewer CD4$^+$ T cells (95%CI: 2.04–1.26; p = 3.28x10$^-$

^{4}) and 1.42-fold fewer CD8$^+$ T cells (95%CI: 1.87–1.07; p = 0.016) (Fig. 4A and Table 5).

Depletion of T cells, then, distinguished MIS-C from both pediatric and adult COVID-19.

Additionally, consistent with the finding in adults hospitalized with COVID-19 (Fig. 3C and

Table 4), after accounting for effect of group, each two-fold decrease in ILC abundance

in pediatric patients hospitalized with COVID-19 or MIS-C was associated with a 40.5

mg/L increase in blood CRP (95% CI: 77.87–3.13; p = 0.035) (Fig. 4C), and no such

association was detected with CD4$^+$ T cells, CD8$^+$ T cells, or CD16+ NK cells.

Table 5: Change in Pediatric Cohort Cell Abundance Due to Age, Sex, and Group

Fold difference (log2) [±95%CI]

	CD4$^+$ T[a]	ILC[a]	CD8$^+$ T[a]	CD16$^+$ NK[a]
Age	-0.004	-0.083**	0.012	0.004
	[-0.027, 0.019]	[-0.135, -0.032]	[-0.014, 0.039]	[-0.060, 0.068]
Male	-0.219	-0.027	0.060	-0.343
	[-0.492, 0.054]	[-0.640, 0.586]	[-0.249, 0.370]	[-1.098, 0.413]
COVID	0.018	-0.754*	-0.088	0.416
	[-0.290, 0.327]	[-1.447, -0.061]	[-0.432, 0.257]	[-0.424, 1.257]
MIS-C	-0.678***	-1.098**	-0.503*	-0.498
	[-1.028, -0.328]	[-1.884, -0.313]	[-0.904, -0.101]	[-1.479, 0.483]
R^2	0.359	0.342	0.169	0.106

* $p < 0.05$, ** $p < 0.01$, *** $p < 0.001$
[a] per 10^6 lymphocytes

The above analysis of lymphoid cell subsets in pediatric COVID-19 and MIS-C was

performed in comparison to pediatric controls alone. Results were essentially unchanged

when multiple linear regression was repeated with combined pediatric and adult control

groups (Fig. 4B, Supplementary Fig. S3, and Supplementary Table S6).

Pediatric MIS-C is distinguished from COVID-19 by recovery of ILCs during follow-

up

The availability of follow-up samples in this pediatric cohort provided the opportunity to

assess the abundance of lymphoid subsets after recovery from illness. To this end, a

linear mixed model was fit to determine the change in ILC abundance from acute illness

to follow-up in 10 individuals (5 COVID-19 and 5 MIS-C) for whom both acute and follow-

up samples were available. After accounting for effects of age, sex, and group, individuals

recovering from MIS-C had a 2.39-fold increase in ILC abundance (95%CI: 1.49–3.81; p

$= 6.6 \times 10^{-3}$) but there was no significant change in ILC abundance for individuals

recovering from COVID-19 (Fig. 4D). Both CD4$^+$ and CD8$^+$ T cells, which were depleted

in MIS-C but not in COVID-19, also increased during recovery from MIS-C and remained

unchanged during recovery from COVID-19 (Supplementary Fig. S4).

The relationship between time to follow-up and lymphoid cell abundance was then

examined for all available follow-up samples whether or not a paired sample from the

acute illness was available (COVID-19, N=14; MIS-C, N=7). This analysis found no

relationship between time to follow-up and abundance of any lymphoid subset, and that

individuals recovering from MIS-C had 2.28-fold more ILCs (95%CI: 1.11–4.69; p =

0.0265) than individuals recovering from COVID-19 (Fig. 4E). There was no difference

between the follow-up groups in CD4$^+$ T cells, CD8$^+$ T cells, or CD16$^+$ NK cells (Fig. 4E).

Interestingly, prior to being hospitalized with MIS-C, only one of these patients had

COVID-19 symptoms and, despite low ILC abundance in the COVID-19 follow-up cohort,

only 28.6% of this group had been ill enough to require hospitalization (Supplementary

Table S2).

Differences between COVID-19 and MIS-C in regards to T cell depletion and ILC

recovery during follow-up indicate that the underlying processes causing lower ILC

abundance in these two SARS-CoV-2-associated diseases are different.

Fig. 4. ILCs are depleted in children with COVID-19 or MIS-C

(**A**) Effect of age (X-axis) on log2 abundance per million lymphocytes of the indicated

lymphoid cell populations (Y-axis), as determined by the regression analysis in Table 5.

Each dot represents an individual blood donor, with yellow for female and blue for male.

Shading represents the 95%CI. P-values are from the regression analysis for

comparisons to the control group.

(**B**) Log2 abundance per million lymphocytes of the indicated lymphoid cell populations,

shown as estimated marginal means with 95%CI, generated from the multiple linear

regressions in Table S6 that included the combined pediatric and adult control data, and

averaged across age and sex. P-values represent pairwise comparisons on the estimated

marginal means, adjusted for multiple comparisons with the Tukey method. Adjusted P-

values < 0.05 are shown.

(**C**) Association of CRP with log2 abundance of ILCs per million lymphocytes. Shading

represents the 95%CI. Each dot represents a single blood donor, orange for COVID-19,

magenta for MIS-C. P-value is for the effect of ILC abundance on CRP as determined by

linear regression.

(**D**) Log2 ILC abundance per million lymphocytes in longitudinal pairs of samples

collected during acute presentation and during follow-up, from individual children with

COVID-19 or MIS-C. Each pair of dots connected by a line represents an individual blood

donor. P-values are for change in ILC abundance at follow-up, as determined with a linear

mixed model, adjusting for age, sex, and group, and with patient as a random effect.

(**E**) Effect of time to follow-up (X-axis) on log2 abundance per million lymphocytes of the

indicated lymphoid cell populations (Y-axis). P-values are for the difference between the

COVID-19 and MIS-C follow-up groups, independent of time to follow-up as determined

by linear regression. Shading represents the 95%CI.

Blood ILCs resemble homeostatic ILCs isolated from lung

In response to the observations described above regarding abundance of blood ILCs and

severity of COVID-19 attempts were made to extend these studies to lung ILCs. It was

not possible to obtain lung samples from people with COVID-19. However, ILCs circulate

from tissues to the bloodstream in lymphatic drainage via the thoracic duct suggesting

that measurement of blood ILCs could provide a surrogate for assessment of tissue-

resident ILCs, including those from the lung. Furthermore, reduction in blood ILCs in

people living with HIV-1 infection is paralleled by decreased ILC numbers within the

lamina propria of the colon (Wang et al., 2020), and so the lower abundance of blood

ILCs associated with severe COVID-19 might be paralleled by decreased abundance of

homeostatic ILCs in the lung.

Given the inability to assess lung samples from people with COVID-19, RNA

sequencing (RNA-Seq) was performed on blood ILCs from nine healthy controls and

these data were compared to previously published RNA-Seq profiles of ILCs sorted from

lung, spleen, and intestine (Ardain et al., 2019; Yudanin et al., 2019). Unbiased principal

component analysis demonstrated overlap of blood ILCs with lung ILCs and clear

separation from ILCs of jejunum or spleen (Fig. 5A). 355 genes were consistently

differentially expressed (fold-change > 1.5, padj < 0.01) when either blood or lung ILCs

were compared to ILCs from the other tissues (Fig. 5B,C). Gene ontology analysis

demonstrated enrichment for terms associated with type 2 immunity (Supplementary

Table S7). Genes significantly higher in both blood and lung ILCs included the ILC2-

defining genes GATA3 and PTGDR2 (CRTH2), as well as other genes important for ILC

development such as TCF7 (Yang et al., 2013) (Fig. 5B,C). As confirmation of the RNA

signature, TCF7- and CRTH2-encoded proteins were detected in blood ILCs by flow

cytometry (Fig. 6A).

Fig. 5. Blood ILCs are transcriptionally similar to lung ILCs

RNA-seq of ILCs sorted from blood of 9 SARS-CoV-2-uninfected controls in comparison

to RNA-seq data of ILCs sorted from jejunum, lung, and spleen.

(**A**) PCA plot of first two principal components calculated from the top 250 most variable

genes across all samples. Each dot represents an individual sample with blue for ILCs

sorted from blood, green for lung, yellow for jejunum, and grey for spleen.

(**B**) Heatmap of 355 genes differentially expressed (fold-change > 1.5, padj < 0.01 as

determined with DESeq2) between either blood or lung ILCs and ILCs from the other

tissues.

(**C**) Select genes from (B) plotted as deseq2 normalized counts. Each dot represents an

individual sample with blue for ILCs sorted from blood, green for lung, yellow for jejunum,

and grey for spleen. Boxplots represent the distribution of the data with the center line

drawn through the median with the upper and lower bounds of the box at the 75th and

25th percentiles respectively. The upper and lower whiskers extend to the largest or

smallest values within 1.5 x the interquartile range (IQR).

Blood ILCs are functional ILC2s capable of producing AREG

To assess the function of blood ILCs, PBMCs were stimulated with PMA and ionomycin, and assayed by flow cytometry for production of IL-13 after intracellular cytokine staining and gating on ILCs. IL-13 was detected in the stimulated ILC population (Fig. 6B), demonstrating that the majority of blood ILCs function as ILC2s. Additionally, the blood ILCs produced amphiregulin (Fig. 6B), a protein implicated in the promotion of disease tolerance by ILCs in animal models (Branzk et al., 2018; Diefenbach et al., 2020; Jamieson et al., 2013; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011).

Females have a higher fraction of amphiregulin-producing blood ILCs than do males

Given the role AREG-producing ILCs play in maintaining disease tolerance in animal models (Branzk et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), sex differences in the functional capability of these ILCs could contribute to the greater risk for severe COVID-19 in males (O'Driscoll et al., 2020). To address this hypothesis, ILCs isolated from peripheral blood of controls were stimulated with PMA and ionomycin, and assayed by flow cytometry for AREG production. Consistent with the apparently lower disease tolerance in males, males had a lower median fraction of AREG[+] ILCs than did females (P=0.018) (Fig. 6C). This difference was also reflected in a significantly lower AREG Mean Fluorescent Intensity (MFI) in males, and neither fraction of AREG[+] ILCs nor AREG MFI was affected by age (Supplementary Fig. S5).

Fig. 6. Peripheral blood ILCs exhibit homeostatic ILC2 functions

(**A-B**) Flow cytometry for the indicated proteins. Cells in (A) were assayed at steady-state

and cells in (B) were assayed either at steady-state or after stimulation with PMA and

ionomycin, as indicated. Detection of surface proteins was performed on ILCs gated as

Lin⁻CD56⁻CD127⁺ and detection of intracellular proteins was performed on ILCs gated as

Lin⁻TBX21⁻CD127⁺.

(**C**) Percent of AREG⁺ ILCs in blood of control blood donors after stimulation with PMA

and ionomycin. Each dot represents an individual blood donor. Boxplots represent the

distribution of the data with the center line drawn through the median with the upper and

lower bounds of the box at the 75th and 25th percentiles respectively. The upper and

lower whiskers extend to the largest or smallest values within 1.5 x the interquartile range

(IQR). P-value is from a two-sided, Wilcoxon rank-sum test.

DISCUSSION

The outcome of SARS-CoV-2 infection ranges from entirely asymptomatic to lethal COVID-19 (Cevik et al., 2021; He et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Richardson et al., 2020; Yang et al., 2021). Yet, viral load does not reliably discriminate asymptomatic from symptomatic or hospitalized populations (Cevik et al., 2021; Jones et al., 2021; Lee et al., 2020; Lennon et al., 2020; Ra et al., 2021; Yang et al., 2021). In contrast, demographic factors, including increasing age and male sex, predict worse outcome of SARS-CoV-2 infection (Alkhouli et al., 2020; Bunders and Altfeld, 2020; Gupta et al., 2021; Laxminarayan et al., 2020; Mauvais-Jarvis, 2020; O'Driscoll et al., 2020; Peckham et al., 2020; Richardson et al., 2020; Scully et al., 2020). These demographic risk factors could be due to sexual dimorphism and changes with aging in composition and function of the human immune system (Darboe et al., 2020; Klein and Flanagan, 2016; Márquez et al., 2020; Patin et al., 2018; Solana et al., 2012). Therefore it is necessary to account for effects of age and sex to determine if there are additional, independent, effects of SARS-CoV-2-associated disease.

This study collected and analyzed 245 blood samples from 177 adult and 58 pediatric patients and controls, spanning the ages of 0.7 to 83 years, with approximately equal numbers of males and females. It was therefore possible to characterize the independent effects of age, sex, COVID-19, and MIS-C on blood lymphoid cell populations. After accounting for effects of age and sex, ILCs, but not $CD4^+$ or $CD8^+$ T cells, were lower in individuals hospitalized with COVID-19 when compared with controls (Table 2 and Fig. 3A,B). Lower numbers of ILCs were also observed in children with COVID-19 (Table 5 and Fig. 4A,B), as well as in an independent cohort of adult patients

(Supplementary Fig. S2). Among adults infected with SARS-CoV-2, lower abundance of

ILCs, but not of the other lymphoid cell subsets, was associated with increased odds of

hospitalization, longer duration of hospitalization, and higher blood level of factors

associated with systemic inflammation, including CRP (Tables 3 and 4, and Fig. 3C). This

inverse relationship between ILC abundance and CRP was also evident in children with

COVID-19 or MIS-C (Fig. 4C).

The identification of reduced ILC numbers as uniquely related to COVID-19

severity is important as these cells mediate disease tolerance in animal models (Artis and

Spits, 2015; Branzk et al., 2018; Califano et al., 2018; Diefenbach et al., 2020; McCarville

and Ayres, 2018; Monticelli et al., 2015, 2011). The results here therefore indicate that

loss of ILCs from blood correlates with loss of ILC-associated homeostatic functions,

thereby allowing more severe COVID-19. Although this study examined circulating blood

lymphoid cells, and does not provide direct information about processes occurring within

tissues, transcriptional and functional characterization of blood ILCs demonstrated that

these cells are similar to ILCs isolated from lung tissue (Fig. 5). Human ILCs circulate in

lymphatic fluid draining from the tissues to the blood via the thoracic duct, raising the

possibility that some ILCs in the blood originate from, or traffic to, lung tissue. Further

characterization of these blood ILCs showed that they are functional ILC2s capable of

producing the protein AREG (Fig. 6A,B). Given the tissue homeostatic role AREG plays

in animal models of disease tolerance (Branzk et al., 2018; Diefenbach et al., 2020;

Jamieson et al., 2013; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), the

discovery here that males have a smaller fraction than females of blood ILCs capable of

producing AREG (Fig. 6C) could explain why males are at greater risk of death from

SARS-CoV-2 infection (O'Driscoll et al., 2020). This sexual dimorphism in ILC function

would be amplified further by the lower overall abundance of ILCs in males (Fig. 2B and

Table 3).

Although the inverse relationship between the number of blood ILCs and severity

of COVID-19 suggests that loss of ILC homeostatic function results in breakdown of

disease tolerance (Arpaia et al., 2015; Artis and Spits, 2015; Branzk et al., 2018;

Diefenbach et al., 2020; McCarville and Ayres, 2018; Monticelli et al., 2015, 2011), this

observational study cannot determine whether ILC depletion preceded SARS-CoV-2

infection or whether ILC numbers are depleted as a consequence of SARS-CoV-2

infection. However, several observations support the hypothesis that individuals with

lower ILC numbers at the time of SARS-CoV-2 infection are at greater risk of developing

severe disease. ILC numbers in uninfected controls decrease exponentially with age; this

decrease is much larger than that seen with other lymphoid cell types (Fig. 2A), and much

more closely mirrors the exponential increase in COVID-19 mortality with age (O'Driscoll

et al., 2020) (Fig. 2C). In addition, the greater risk of COVID-19 mortality in males

(O'Driscoll et al., 2020) correlates with lower abundance of blood ILCs (Fig. 2B and Table

3) and smaller fraction of ILCs capable of producing AREG (Fig. 6C). Further supporting

this hypothesis is the observation that conditions independently associated with lower ILC

abundance, such as HIV-1 infection (Kløverpris et al., 2016; Wang et al., 2020) and

obesity (Brestoff et al., 2015; Yudanin et al., 2019), increase the risk for worse outcomes

from SARS-CoV-2 infection (Biccard et al., 2021; Kompaniyets, 2021; Tesoriero et al.,

2021).

In contrast to individuals with COVID-19, children with MIS-C had lower numbers

of T cells as well as ILCs (Table 5 and Fig. 4A,B), and longitudinal follow-up samples for

pediatric COVID-19 and MIS-C patients showed persistence of low ILC numbers after

COVID-19, but normalization of all depleted cell types after recovery from MIS-C (Fig.

4D,E and Supplementary Fig. S4). These differences imply that the reversible

lymphopenia in MIS-C is due to different underlying processes than the more specific and

persistent lower ILC abundance seen in individuals with COVID-19. This difference is

made more interesting by the fact that none of the children with MIS-C had required

hospitalization for COVID-19 and only one experienced any COVID-19 symptoms. The

other children with MIS-C were therefore unaware that they had been infected. It is

possible that children with pre-existing lower ILC numbers are at risk of developing

COVID-19 if infected with SARS-CoV-2, while other factors such as prolonged exposure

to SARS-CoV-2 antigens in the gastrointestinal tract (Yonker et al., 2021), or rare inborn

errors of immunity (Sancho-Shimizu et al., 2021), promote inflammatory processes in

MIS-C that drive nonspecific lymphoid cell depletion, which ultimately normalizes after

recovery.

Although ILC depletion and recovery has been reported in rheumatoid arthritis

(Rauber et al., 2017), inflammation-driven ILC-depletion is not necessarily reversible, as

ILCs appear permanently depleted after HIV-1 infection, possibly by high levels of

common γ-chain cytokines during acute infection (Wang et al., 2020). Better

understanding of the processes that drive down ILC abundance in populations

susceptible to COVID-19 could potentially allow for development of interventions that

increase ILC abundance and restore homeostatic disease tolerance mechanisms.

In conclusion, considering the established homeostatic function of ILCs (Artis and

Spits, 2015; Branzk et al., 2018; Klose and Artis, 2016; Monticelli et al., 2015, 2011) and

presumed non-immunologic, host adaptive responses necessary to survive pathogenic

infection (López-Otín and Kroemer, 2021; McCarville and Ayres, 2018; Medzhitov et al.,

2012; Schneider and Ayres, 2008), the findings reported here support the hypothesis that

loss of disease tolerance mechanisms attributable to ILCs increase the risk of morbidity

and mortality with SARS-CoV-2 infection. The findings of this observational study warrant

establishment of prospective cohorts to determine whether abundance of ILCs or of other

lymphoid cell subsets associated with disease tolerance (Arpaia et al., 2015; Artis and

Spits, 2015; Branzk et al., 2018; Diefenbach et al., 2020; McCarville and Ayres, 2018;

Monticelli et al., 2015, 2011), predict clinical outcome for infection with SARS-CoV-2 or

other lethal pathogens. Understanding the mechanisms that allow an individual to tolerate

high-level viral replication without experiencing symptoms, and how these mechanisms

can fail and thereby allow for progression to severe disease, will provide the foundation

for development of therapeutic interventions that maintain health and improve survival of

pathogenic viral infection (Ayres, 2020b).

646
647

Materials and Methods

Data availability

The data that support the findings of this study are available within the manuscript and in its supplementary information files. Bulk RNA-seq datasets generated here can be found at: NCBI Gene Expression Omnibus (GEO): GSE168212. Bulk RNA-seq data generated by previously-published studies are available from NCBI GEO: GSE131031 and GSE126107. This study did not generate unique code. Any additional information required to reanalyze the data reported in this paper is available from the lead contact upon request.

Peripheral blood PBMCs

As part of a COVID-19 observational study, peripheral blood samples were collected from 91 adults with SARS-CoV-2 infection at the Massachusetts General Hospital and affiliated outpatient clinics. Request for access to coded patient samples was reviewed by the Massachusetts Consortium for Pathogen Readiness (https://masscpr.hms.harvard.edu/), and approved by the University of Massachusetts Medical School IRB (protocol #H00020836). Pediatric participants with COVID-19 or MIS-C were enrolled in the Massachusetts General Hospital Pediatric COVID-19 Biorepository (MGB IRB # 2020P000955); healthy pediatric controls were enrolled in the Pediatric Biorepository (MGB IRB # 2016P000949). Samples were collected after obtaining consent from the patient if 18 years or older, or from the parent/guardian, plus assent when appropriate. Demographic, laboratory, and clinical outcome data were included with the coded samples. Samples from 86 adult blood donors and 17 pediatric blood donors, either

collected prior to the SARS-CoV-2 outbreak, or from healthy individuals screened at a

blood bank, were included as controls.

Human mononuclear cell isolation

Human peripheral blood was diluted in an equal volume of RPMI-1640 (Gibco), overlaid

on Lymphoprep (STEMSELL, 07851), and centrifuged at 500 x g at room temperature for

30 minutes. Mononuclear cells were washed 3 times with MACS buffer (0.5% BSA and 2

mM EDTA in PBS) and frozen in FBS containing 10% DMSO.

678
679
Flow cytometry

Peripheral blood mononuclear cells (PBMCs) were first stained with Live and Dead violet

viability kit (Invitrogen, L-34963). To detect surface molecules, cells were stained in

MACS buffer with antibodies (Supplementary Table S8) for 30 min at 4°C in the dark. To

detect IL-13 or AREG, cells were stimulated with PMA and ionomycin (eBioscience, 00-

4970-03) for 3 hours with Brefeldin A and Monensin (eBioscience, 00-4980-03) present

during the stimulation. To detect transcription factors or cytokines, cells were fixed and

permeabilized using Foxp3 staining buffer kit (eBioscience, 00-5523-00), then

intracellular molecules were stained in permeabilization buffer with antibodies. Cells were

detected on a BD Celesta flow cytometer using previously established gating strategies

(Wang et al., 2020). Cell subsets were identified using FlowJo™ software (Becton,

Dickson and Company). Representative gating strategies are shown in Fig. S6.

Bulk RNA-Seq Library preparation of PBMC ILCs

The sequencing libraries were prepared using CEL-Seq2 (Hashimshony et al., 2016). RNA from sorted cells was extracted using TRIzol reagent (ThermoFisher, 15596018). 10 ng RNA was used for first strand cDNA synthesis using barcoded primers (the specific primers for each sample were listed in Supplementary Table S9). The second strand was synthesized by NEBNext Second Strand Synthesis Module (NEB, E6111L). The pooled dsDNA was purified with AMPure XP beads (Beckman Coulter, A63880), and subjected to in vitro transcription (IVT) using HiScribe T7 High Yield RNA Synthesis Kit (NEB, E2040S), then treated with ExoSAP-IT (Affymetrix, 78200). IVT RNA was fragmented using RNA fragmentation reagents (Ambion), and underwent another reverse transcription step using random hexamer RT primer-5'-GCC TTG GCA CCC GAG AAT TCC ANN NNN N-3' to incorporate the second adapter. The final library was amplified with indexed primers: RP1 and RPI1 (Supplementary Table S9), and the bead purified library was quantified with 4200 TapeStation (Agilent Technologies), and paired-end sequenced on Nextseq 500 V2 (Illumina), Read 1: 15 cycles; index 1: 6 cycles; Read 2: 60 cycles.

RNA-seq analyses

Pooled reads from PBMC ILCs were separated by CEL-Seq2 barcodes, and demultiplexed reads from RNA-seq of ILCs from lung (Ardain et al., 2019), spleen and intestine (Yudanin et al., 2019), were downloaded from GSE131031 and GSE126107. Within the DolphinNext RNA-seq pipeline (Revision 4) (Yukselen et al., 2020), reads were aligned to the hg19 genome using STAR (version 2.1.6) (Dobin et al., 2013) and counts

of reads aligned to RefSeq genes were quantified using RSEM (version 1.3.1) (Li and

Dewey, 2011). Normalized transcript abundance in the form of TPMs were used to filter

out low abundance transcripts with an average of <3 TPMs across libraries. RSEM-

generated expected counts were normalized and differential analysis was performed

using DEseq2 (Love et al., 2014) in R, with significant genes defined as a greater than

1.5-fold difference and an adjusted p-value <0.01. GO Enrichment Analysis was

performed in R using the enrichGO function in the clusterProfiler R package (Yu et al.,

2012). Data were transformed using vsd within DEseq2 both for the heatmap visualization

with ComplexHeatmap (Gu et al., 2016) and for principal component analysis (PCA) with

prcomp on the top 250 most variable genes. Normalized counts were generated for

plotting using the counts command in Deseq2.

Statistical analysis and data visualization

Data were prepared for analysis with tidyverse packages (Wickham et al., 2019) and

visualized using the ggplot2 (Wickham, 2016), ggpubr (Kassambara, 2020), and

ComplexHeatmap (Gu et al., 2016) packages, within the R computer software

environment (version 4.0.2) (R Core Team, 2020). Group differences were determined

with pairwise, two-sided, Wilcoxon rank-sum tests, or Fisher's exact test, as indicated,

with Bonferroni correction for multiple comparisons. Multiple linear regression analyses

were performed with dependent and independent variables as indicated in the text, using

the lm function in R. Pairwise group comparisons on estimated marginal means

generated from multiple linear regression were performed using the emmeans package

(Lenth, 2020) in R, with multiple comparison correction using the Tukey adjustment.

Multiple logistic regressions were performed using the glm function in R. Longitudinal

follow-up analyses on pediatric COVID-19 and MIS-C was performed with linear mixed-

effect models using lme4 (Bates et al., 2015) in R with the equation: log2 (lymphoid cell

abundance) ~ Age + Sex + Group + Group:Follow_up + (1|Patient_ID). This model tested

the effect of followup on ILC abundance in the pediatric COVID-19 and MIS-C groups

while accounting for age, sex, and group. Statistical significance was determined with

lmerTest (Kuznetsova et al., 2017) in R, using the Satterthwarte's degrees of freedom

method. $p < 0.05$ was considered significant. United States SARS-CoV-2 infection and

mortality data were downloaded from (CDC Case Surveillance Task Force, 2020) and

cases with age group and outcome available were plotted by age group as indicated.

Mortality rate was calculated by dividing the number of fatal cases by the total number of

cases with known outcome in each age group as indicated.

REFERENCES

Alghamdi IG, Hussain II, Almalki SS, Alghamdi MS, Alghamdi MM, El-Sheemy MA. 2014. The pattern of Middle East respiratory syndrome coronavirus in Saudi Arabia: a descriptive epidemiological analysis of data from the Saudi Ministry of Health. *Int J Gen Med* **7**:417.

Alkhouli M, Nanjundappa A, Annie F, Bates MC, Bhatt DL. 2020. Sex Differences in Case Fatality Rate of COVID-19: Insights From a Multinational Registry. *Mayo Clin Proc* **95**:1613–1620.

Anegon I, Cuturi MC, Trinchieri G, Perussia B. 1988. Interaction of Fc receptor (CD16) ligands induces transcription of interleukin 2 receptor (CD25) and lymphokine genes and expression of their products in human natural killer cells. *J Exp Med* **167**:452–472.

Ardain A, Domingo-Gonzalez R, Das S, Kazer SW, Howard NC, Singh A, Ahmed M, Nhamoyebonde S, Rangel-Moreno J, Ogongo P, Lu L, Ramsuran D, de la Luz Garcia-Hernandez M, K. Ulland T, Darby M, Park E, Karim F, Melocchi L, Madansein R, Dullabh KJ, Dunlap M, Marin-Agudelo N, Ebihara T, Ndung'u T, Kaushal D, Pym AS, Kolls JK, Steyn A, Zúñiga J, Horsnell W, Yokoyama WM, Shalek AK, Kløverpris HN, Colonna M, Leslie A, Khader SA. 2019. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis. *Nature* **570**:528–532.

Arpaia N, Green JA, Moltedo B, Arvey A, Hemmers S, Yuan S, Treuting PM, Rudensky AY. 2015. A Distinct Function of Regulatory T Cells in Tissue Protection. *Cell* **162**:1078–1089.

Artis D, Spits H. 2015. The biology of innate lymphoid cells. *Nature* **517**:293–301.

Ayres JS. 2020a. The Biology of Physiological Health. *Cell* **181**:250–269.

Ayres JS. 2020b. Surviving COVID-19: A disease tolerance perspective. *Sci Adv*
6:eabc1518.

Bates D, Mächler M, Bolker B, Walker S. 2015. Fitting Linear Mixed-Effects Models
Usinglme4. *Journal of Statistical Software*. doi:10.18637/jss.v067.i01

Biccard BM, Gopalan PD, Miller M, Michell WL, Thomson D, Ademuyiwa A, Aniteye E,
Calligaro G, Chaibou MS, Dhufera HT, Elfagieh M, Elfiky M, Elhadi M, Fawzy M,
Fredericks D, Gebre M, Bayih AG, Hardy A, Joubert I, Kifle F, Kluyts H-L, Macleod
K, Mekonnen Z, Mer M, Morais A, Msosa V, Mulwafu W, Ndonga A, Ngumi Z,
Omigbodun A, Owoo C, Paruk F, Piercy JL, Scribante J, Seman Y, Taylor E, van
Straaten D, Elfiky M, Fawzy M, Awad A, Hussein H, Shaban M, Elbadawy M,
Elmehrath AO, Cordie A, Elganainy M, El-Shazly M, Essam M, Abdelwahab OA,
Ali A, Hussein AM, Kamel EZ, Monib FA, Ahmed I, Saad MM, Al-Quossi MA,
Rafaat N, Galal I, Labib B, Omran DO, Fawzy M, Elfiky M, Azzam Ahmed, Azab
M, Tawheed A, Gamal M, El Kassas M, Azzam Aml, Ahmed N, NasrEldin Y,
Abdewahab O, Elganainy M, Elmandouh O, Dhufera HT, MeGebre M, Bayih AG,
Kifle F, Mekonnen Z, Seman Y, Addisie A, Eshete A, Kifle F, Desita K, Araya H,
Agidew Y, Andabo AD, Tesfaye E, Yesuf EA, Hailemariam G, Mohammed MS,
Gebremedhin Y, Taye Y, Mebrate TA, Gemechu TB, Bedane TT, Abera ET,
Teshome A, Ernest Aniteye EA, Christian Owoo CO, Doku A, Owoo C, Afriyie-
Mensah JS, Lawson A, Owoo C, DYaw Sottie DA, Addae E, Ernest Ofosu-Appiah
EO-A, William Obeng WO, Ndonga A, Ngumi Z, Ndonga A, Mugera A, Bitta C,

Elfagieh M, Elhadi M, Huwaysh MA, Yahya MMA, Mohammed AAK, Majeed AAM,

Mohammed AEM, Majeed E, Abusalama AA, Altayr E, Abubaker T, Alkaseek AM,

Abdulhafith B, Alziyituni Z, Gamra MF, Anaiba MM, Khel S, Abdelkabir M, Abdeewi

S, Adam S, Alhadi A, Alsoufi A, Hassan M, Msherghi A, Bouhuwaish AEM, Msosa

V, Mulwafu W, Masoo F, Chikumbanje SS, Mabedi D, Morais A, Carlos A, Morais

A, Lorenzoni C, Mambo J, Isabel Chissaque I, Mouzinho Saide M, Chaibou MS,

Mamane M, Amadou F, Adesoji Ademuyiwa AA, Akinyinka Omigbodun AO,

Adeyeye A, Akinmade A, Momohsani Y, Bamigboye J, Orshio D, Isamade ES,

Embu H, Nuhu S, Ojiakor S, Nuhu A, Fowotade A, Sanusi A, Osinaike B, Idowu O,

Amali AO, Ibrahim S, Adamu AA, Kida I, Otokwala J, Essam M, Alagbe-Briggs O,

Ojum S, Fathima Paruk FP, Juan Scribante JS, Mdladla A, Mabotja T, Naidoo R,

Matos-Puig R, Ramkillawan A, Smith M, Arnold-Day C, Thomson D, Calligaro G,

Joubert I, Jagga J, Piercy J, Michell L, Devenish L, Miller M, Fernandes N, Gopalan

D, Pershad S, Grabowski N, Rammego M, Zwane S, Dhlamini ME, Neuhoff M,

Fodo T, Usenbo A, Mrara B, Kabambi F, Cloete E, De Caires L, Dickerson R, Louw

C, Theron A, Herselman R, Badenhorst J, Moletsane G, Loots H, Paruk F,

Chausse J, Neuhoff M, Sebastian M, Grabowski N, Rheeder P, van Hougenhouck-

Tulleken W, Snyman C, Adeleke D, Esterhuizen J, de Man L, Mosola M, van der

Linde P, Swart R, Maasdorp S, Martins T, Govender V. 2021. Patient care and

clinical outcomes for patients with COVID-19 infection admitted to African high-

care or intensive care units (ACCCOS): a multicentre, prospective, observational

cohort study. *Lancet* **397**:1885–1894.

Branzk N, Gronke K, Diefenbach A. 2018. Innate lymphoid cells, mediators of tissue homeostasis, adaptation and disease tolerance. *Immunol Rev* **286**:86–101.

Brestoff JR, Kim BS, Saenz SA, Stine RR, Monticelli LA, Sonnenberg GF, Thome JJ, Farber DL, Lutfy K, Seale P, Artis D. 2015. Group 2 innate lymphoid cells promote beiging of white adipose tissue and limit obesity. *Nature* **519**:242–246.

Bunders MJ, Altfeld M. 2020. Implications of Sex Differences in Immunity for SARS-CoV-2 Pathogenesis and Design of Therapeutic Interventions. *Immunity* **53**:487–495.

Califano D, Furuya Y, Roberts S, Avram D, McKenzie ANJ, Metzger DW. 2018. IFN-γ increases susceptibility to influenza A infection through suppression of group II innate lymphoid cells. *Mucosal Immunol* **11**:209–219.

CDC Case Surveillance Task Force. 2020. COVID-19 Case Surveillance Public Use Data.

Cevik M, Tate M, Lloyd O, Maraolo AE, Schafers J, Ho A. 2021. SARS-CoV-2, SARS-CoV, and MERS-CoV viral load dynamics, duration of viral shedding, and infectiousness: a systematic review and meta-analysis. *The Lancet Microbe* **2**:e13–e22.

Channappanavar R, Fett C, Mack M, Ten Eyck PP, Meyerholz DK, Perlman S. 2017. Sex-Based Differences in Susceptibility to Severe Acute Respiratory Syndrome Coronavirus Infection. *J Immunol* **198**:4046–4053.

Charles Bailey L, Razzaghi H, Burrows EK, Timothy Bunnell H, Camacho PEF, Christakis DA, Eckrich D, Kitzmiller M, Lin SM, Magnusen BC, Newland J, Pajor NM, Ranade D, Rao S, Sofela O, Zahner J, Bruno C, Forrest CB. 2020. Assessment of 135 794

Pediatric Patients Tested for Severe Acute Respiratory Syndrome Coronavirus 2

Across the United States. *JAMA Pediatr*. doi:10.1001/jamapediatrics.2020.5052

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang Xiaoyun, Chen H, Yu

H, Zhang Xiaoping, Zhang M, Wu S, Song J, Chen T, Han M, Li S, Luo X, Zhao J,

Ning Q. 2020. Clinical and immunological features of severe and moderate

coronavirus disease 2019. *J Clin Invest* **130**:2620–2629.

Chen J, Subbarao K. 2007. The Immunobiology of SARS. *Annu Rev Immunol* **25**:443–

472.

Cherrier DE, Serafini N, Di Santo JP. 2018. Innate Lymphoid Cell Development: A T Cell

Perspective. *Immunity* **48**:1091–1103.

Cheung EW, Zachariah P, Gorelik M, Boneparth A, Kernie SG, Orange JS, Milner JD.

2020. Multisystem Inflammatory Syndrome Related to COVID-19 in Previously

Healthy Children and Adolescents in New York City. *JAMA* **324**:294–296.

Cumnock K, Gupta AS, Lissner M, Chevee V, Davis NM, Schneider DS. 2018. Host

Energy Source Is Important for Disease Tolerance to Malaria. *Curr Biol* **28**:1635-

1642.e3.

Darboe A, Nielsen CM, Wolf A-S, Wildfire J, Danso E, Sonko B, Bottomley C, Moore SE,

Riley EM, Goodier MR. 2020. Age-Related Dynamics of Circulating Innate

Lymphoid Cells in an African Population. *Front Immunol* **11**:594107.

Diefenbach A, Gnafakis S, Shomrat O. 2020. Innate Lymphoid Cell-Epithelial Cell

Modules Sustain Intestinal Homeostasis. *Immunity* **52**:452–463.

Dobin A, Davis CA, Schlesinger F, Drenkow J, Zaleski C, Jha S, Batut P, Chaisson M,

Gingeras TR. 2013. STAR: ultrafast universal RNA-seq aligner. *Bioinformatics*

29:15–21.

Donnelly CA, Ghani AC, Leung GM, Hedley AJ, Fraser C, Riley S, Abu-Raddad LJ, Ho

L-M, Thach T-Q, Chau P, Chan K-P, Lam T-H, Tse L-Y, Tsang T, Liu S-H, Kong

JHB, Lau EMC, Ferguson NM, Anderson RM. 2003. Epidemiological determinants

of spread of causal agent of severe acute respiratory syndrome in Hong Kong.

Lancet **361**:1761–1766.

D'Souza SS, Shen X, Fung ITH, Ye L, Kuentzel M, Chittur SV, Furuya Y, Siebel CW,

Maillard IP, Metzger DW, Yang Q. 2019. Compartmentalized effects of aging on

group 2 innate lymphoid cell development and function. *Aging Cell*.

doi:10.1111/acel.13019

Feldstein LR, Rose EB, Horwitz SM, Collins JP, Newhams MM, Son MBF, Newburger

JW, Kleinman LC, Heidemann SM, Martin AA, Singh AR, Li S, Tarquinio KM, Jaggi

P, Oster ME, Zackai SP, Gillen J, Ratner AJ, Walsh RF, Fitzgerald JC, Keenaghan

MA, Alharash H, Doymaz S, Clouser KN, Giuliano JS Jr, Gupta A, Parker RM,

Maddux AB, Havalad V, Ramsingh S, Bukulmez H, Bradford TT, Smith LS,

Tenforde MW, Carroll CL, Riggs BJ, Gertz SJ, Daube A, Lansell A, Coronado

Munoz A, Hobbs CV, Marohn KL, Halasa NB, Patel MM, Randolph AG,

Overcoming COVID-19 Investigators, CDC COVID-19 Response Team. 2020.

Multisystem Inflammatory Syndrome in U.S. Children and Adolescents. *N Engl J*

Med **383**:334–346.

Feldstein LR, Tenforde MW, Friedman KG, Newhams M, Rose EB, Dapul H, Soma VL,

Maddux AB, Mourani PM, Bowens C, Maamari M, Hall MW, Riggs BJ, Giuliano JS

Jr, Singh AR, Li S, Kong M, Schuster JE, McLaughlin GE, Schwartz SP, Walker

TC, Loftis LL, Hobbs CV, Halasa NB, Doymaz S, Babbitt CJ, Hume JR, Gertz SJ,

Irby K, Clouser KN, Cvijanovich NZ, Bradford TT, Smith LS, Heidemann SM,

Zackai SP, Wellnitz K, Nofziger RA, Horwitz SM, Carroll RW, Rowan CM,

Tarquinio KM, Mack EH, Fitzgerald JC, Coates BM, Jackson AM, Young CC, Son

MBF, Patel MM, Newburger JW, Randolph AG, Overcoming COVID-19

Investigators. 2021. Characteristics and Outcomes of US Children and

Adolescents With Multisystem Inflammatory Syndrome in Children (MIS-C)

Compared With Severe Acute COVID-19. *JAMA*. doi:10.1001/jama.2021.2091

Flanagan KL, Fink AL, Plebanski M, Klein SL. 2017. Sex and Gender Differences in the

Outcomes of Vaccination over the Life Course. *Annu Rev Cell Dev Biol* **33**:577–

599.

Gallo Marin B, Aghagoli G, Lavine K, Yang L, Siff EJ, Chiang SS, Salazar-Mather TP,

Dumenco L, Savaria MC, Aung SN, Flanigan T, Michelow IC. 2020. Predictors of

COVID-19 severity: A literature review. *Rev Med Virol* e2146.

García M, Kokkinou E, Carrasco García A, Parrot T, Palma Medina LM, Maleki KT, Christ

W, Varnaitė R, Filipovic I, Ljunggren H-G, Others. 2020. Innate lymphoid cell

composition associates with COVID-19 disease severity. *Clinical & translational*

immunology **9**:e1224.

Giefing-Kröll C, Berger P, Lepperdinger G, Grubeck-Loebenstein B. 2015. How sex and
915   age affect immune responses, susceptibility to infections, and response to
916   vaccination. *Aging Cell* **14**:309–321.

917   Gu Z, Eils R, Schlesner M. 2016. Complex heatmaps reveal patterns and correlations in
918   multidimensional genomic data. *Bioinformatics* **32**:2847–2849.

919   Gupta RK, Harrison EM, Ho A, Docherty AB, Knight SR, van Smeden M, Abubakar I,
920   Lipman M, Quartagno M, Pius R, Buchan I, Carson G, Drake TM, Dunning J,
921   Fairfield CJ, Gamble C, Green CA, Halpin S, Hardwick HE, Holden KA, Horby PW,
922   Jackson C, Mclean KA, Merson L, Nguyen-Van-Tam JS, Norman L, Olliaro PL,
923   Pritchard MG, Russell CD, Scott-Brown J, Shaw CA, Sheikh A, Solomon T, Sudlow
924   C, Swann OV, Turtle L, Openshaw PJM, Baillie JK, Semple MG, Noursadeghi M,
925   ISARIC4C Investigators. 2021. Development and validation of the ISARIC 4C
926   Deterioration model for adults hospitalised with COVID-19: a prospective cohort
927   study. *Lancet Respir Med*. doi:10.1016/S2213-2600 (20)30559-2

928   Hashimshony T, Senderovich N, Avital G, Klochendler A, de Leeuw Y, Anavy L, Gennert
929   D, Li S, Livak KJ, Rozenblatt-Rosen O, Dor Y, Regev A, Yanai I. 2016. CEL-Seq2:
930   sensitive highly-multiplexed single-cell RNA-Seq. *Genome Biol* **17**:77.

931   He J, Guo Y, Mao R, Zhang J. 2021. Proportion of asymptomatic coronavirus disease
932   2019: A systematic review and meta-analysis. *J Med Virol* **93**:820–830.

933   Heald-Sargent T, Muller WJ, Zheng X, Rippe J, Patel AB, Kociolek LK. 2020. Age-Related
934   Differences in Nasopharyngeal Severe Acute Respiratory Syndrome Coronavirus
935   2 (SARS-CoV-2) Levels in Patients With Mild to Moderate Coronavirus Disease
936   2019 (COVID-19). *JAMA Pediatr* **174**:902–903.

Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu
T, Xia J, Wei Y, Wu W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J,
Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao B. 2020. Clinical features of patients
infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**:497–506.

Huang I, Pranata R. 2020. Lymphopenia in severe coronavirus disease-2019 (COVID-
19): systematic review and meta-analysis. *J Intensive Care Med* **8**:36.

Jamieson AM, Pasman L, Yu S, Gamradt P, Homer RJ, Decker T, Medzhitov R. 2013.
Role of tissue protection in lethal respiratory viral-bacterial coinfection. *Science*
340:1230–1234.

Jhaveri KA, Trammell RA, Toth LA. 2007. Effect of environmental temperature on sleep,
locomotor activity, core body temperature and immune responses of C57BL/6J
mice. *Brain Behav Immun* **21**:975–987.

Jones TC, Biele G, Mühlemann B, Veith T, Schneider J, Beheim-Schwarzbach J, Bleicker
T, Tesch J, Schmidt ML, Sander LE, Kurth F, Menzel P, Schwarzer R, Zuchowski
M, Hofmann J, Krumbholz A, Stein A, Edelmann A, Corman VM, Drosten C. 2021.
Estimating infectiousness throughout SARS-CoV-2 infection course. *Science*
373:eabi5273.

Karlberg J. 2004. Do Men Have a Higher Case Fatality Rate of Severe Acute Respiratory
Syndrome than Women Do? *American Journal of Epidemiology*.
doi:10.1093/aje/kwh056

Kassambara A. 2020. ggpubr: "ggplot2" Based Publication Ready Plots.

Klein SL, Flanagan KL. 2016. Sex differences in immune responses. *Nat Rev Immunol*
16:626–638.

Klose CSN, Artis D. 2016. Innate lymphoid cells as regulators of immunity, inflammation

and tissue homeostasis. *Nat Immunol* **17**:765–774.

Kløverpris HN, Kazer SW, Mjösberg J, Mabuka JM, Wellmann A, Ndhlovu Z, Yadon MC,

Nhamoyebonde S, Muenchhoff M, Simoni Y, Andersson F, Kuhn W, Garrett N,

Burgers WA, Kamya P, Pretorius K, Dong K, Moodley A, Newell EW, Kasprowicz

V, Abdool Karim SS, Goulder P, Shalek AK, Walker BD, Ndung'u T, Leslie A. 2016.

Innate Lymphoid Cells Are Depleted Irreversibly during Acute HIV-1 Infection in

the Absence of Viral Suppression. *Immunity* **44**:391–405.

Kompaniyets L. 2021. Body Mass Index and Risk for COVID-19–Related Hospitalization,

Intensive Care Unit Admission, Invasive Mechanical Ventilation, and Death —

United States, March–December 2020. *MMWR Morb Mortal Wkly Rep* **70**.

doi:10.15585/mmwr.mm7010e4

Kuri-Cervantes L, Pampena MB, Meng W, Rosenfeld AM, Ittner CAG, Weisman AR,

Agyekum RS, Mathew D, Baxter AE, Vella LA, Kuthuru O, Apostolidis SA, Bershaw

L, Dougherty J, Greenplate AR, Pattekar A, Kim J, Han N, Gouma S, Weirick ME,

Arevalo CP, Bolton MJ, Goodwin EC, Anderson EM, Hensley SE, Jones TK,

Mangalmurti NS, Luning Prak ET, Wherry EJ, Meyer NJ, Betts MR. 2020.

Comprehensive mapping of immune perturbations associated with severe COVID-

19. *Sci Immunol* **5**:eabd7114.

Kuznetsova A, Brockhoff PB, Christensen RHB, Others. 2017. lmerTest package: tests

in linear mixed effects models. *J Stat Softw* **82**:1–26.

981 Laxminarayan R, Wahl B, Dudala SR, Gopal K, Mohan B C, Neelima S, Jawahar Reddy

982   KS, Radhakrishnan J, Lewnard JA. 2020. Epidemiology and transmission

983   dynamics of COVID-19 in two Indian states. *Science* **370**:691–697.

984 Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son H-J, Yu S, Park JW, Choo EJ,

985   Park S, Loeb M, Kim TH. 2020. Clinical Course and Molecular Viral Shedding

986   Among Asymptomatic and Symptomatic Patients With SARS-CoV-2 Infection in a

987   Community Treatment Center in the Republic of Korea. *JAMA Internal Medicine*

988   **180**:1447.

989 Leist SR, Dinnon KH 3rd, Schäfer A, Tse LV, Okuda K, Hou YJ, West A, Edwards CE,

990   Sanders W, Fritch EJ, Gully KL, Scobey T, Brown AJ, Sheahan TP, Moorman NJ,

991   Boucher RC, Gralinski LE, Montgomery SA, Baric RS. 2020. A Mouse-Adapted

992   SARS-CoV-2 Induces Acute Lung Injury and Mortality in Standard Laboratory

993   Mice. *Cell* **183**:1070-1085.e12.

994 Lennon NJ, Bhattacharyya RP, Mina MJ, Rehm HL, Hung DT, Smole S, Woolley A,

995   Lander ES, Gabriel SB. 2021. Cross-sectional assessment of SARS-CoV-2 viral

996   load by symptom status in Massachusetts congregate living facilities. *J Infect Dis*.

997   doi:10.1093/infdis/jiab367

998 Lennon NJ, Bhattacharyya RP, Mina MJ, Rehm HL, Hung DT, Smole S, Woolley A,

999   Lander ES, Gabriel SB. 2020. Comparison of viral levels in individuals with or

1000   without symptoms at time of COVID-19 testing among 32,480 residents and staff

1001   of nursing homes and assisted living facilities in Massachusetts. *bioRxiv*.

1002   doi:10.1101/2020.07.20.20157792

1003 Lenth R. 2020. emmeans: Estimated Marginal Means, aka Least-Squares Means.

Li B, Dewey CN. 2011. RSEM: accurate transcript quantification from RNA-Seq data with

or without a reference genome. *BMC Bioinformatics* **12**:323.

Li B, Zhang S, Zhang R, Chen X, Wang Y, Zhu C. 2020. Epidemiological and Clinical

Characteristics of COVID-19 in Children: A Systematic Review and Meta-Analysis.

Front Pediatr **8**:591132.

Licciardi F, Pruccoli G, Denina M, Parodi E, Taglietto M, Rosati S, Montin D. 2020. SARS-

CoV-2-Induced Kawasaki-Like Hyperinflammatory Syndrome: A Novel COVID

Phenotype in Children. *Pediatrics*. doi:10.1542/peds.2020-1711

López-Otín C, Kroemer G. 2021. Hallmarks of Health. *Cell* **184**:33–63.

LoTempio JE, Billings EA, Draper K, Ralph C, Moshgriz M, Duong N, Bard JD, Gai X,

Wessel D, DeBiasi RL, Campos JM, Vilain E, Delaney M, Michael DG. 2021. Novel

SARS-CoV-2 spike variant identified through viral genome sequencing of the

pediatric Washington D.C. COVID-19 outbreak. *medRxiv* 2021.02.08.21251344.

Love M, Anders S, Huber W. 2014. Differential analysis of count data--the DESeq2

package. *Genome Biol* **15**:550.

Lu X, Zhang L, Du H, Zhang J, Li YY, Qu J, Zhang W, Wang Y, Bao S, Li Y, Wu C, Liu H,

Liu D, Shao J, Peng X, Yang Y, Liu Z, Xiang Y, Zhang F, Silva RM, Pinkerton KE,

Shen K, Xiao H, Xu S, Wong GWK, Chinese Pediatric Novel Coronavirus Study

Team. 2020. SARS-CoV-2 Infection in Children. *N Engl J Med* **382**:1663–1665.

Lucas C, Wong P, Klein J, Castro TBR, Silva J, Sundaram M, Ellingson MK, Mao T, Oh

JE, Israelow B, Takahashi T, Tokuyama M, Lu P, Venkataraman A, Park A,

Mohanty S, Wang H, Wyllie AL, Vogels CBF, Earnest R, Lapidus S, Ott IM, Moore

AJ, Muenker MC, Fournier JB, Campbell M, Odio CD, Casanovas-Massana A,

Yale IMPACT Team, Herbst R, Shaw AC, Medzhitov R, Schulz WL, Grubaugh ND,

Dela Cruz C, Farhadian S, Ko AI, Omer SB, Iwasaki A. 2020. Longitudinal

analyses reveal immunological misfiring in severe COVID-19. *Nature* **584**:463–

469.

Luo X, Zhou W, Yan X, Guo T, Wang B, Xia H, Ye L, Xiong J, Jiang Z, Liu Y, Zhang B,

Yang W. 2020. Prognostic Value of C-Reactive Protein in Patients With

Coronavirus 2019. *Clin Infect Dis* **71**:2174–2179.

Márquez EJ, Chung C-H, Marches R, Rossi RJ, Nehar-Belaid D, Eroglu A, Mellert DJ,

Kuchel GA, Banchereau J, Ucar D. 2020. Sexual-dimorphism in human immune

system aging. *Nat Commun* **11**:751.

Mathew D, Giles JR, Baxter AE, Oldridge DA, Greenplate AR, Wu JE, Alanio C, Kuri-

Cervantes L, Pampena MB, D'Andrea K, Manne S, Chen Z, Huang YJ, Reilly JP,

Weisman AR, Ittner CAG, Kuthuru O, Dougherty J, Nzingha K, Han N, Kim J,

Pattekar A, Goodwin EC, Anderson EM, Weirick ME, Gouma S, Arevalo CP,

Bolton MJ, Chen F, Lacey SF, Ramage H, Cherry S, Hensley SE, Apostolidis SA,

Huang AC, Vella LA, UPenn COVID Processing Unit, Betts MR, Meyer NJ, Wherry

EJ. 2020. Deep immune profiling of COVID-19 patients reveals distinct

immunotypes with therapeutic implications. *Science* **369**.

doi:10.1126/science.abc8511

Mauvais-Jarvis F. 2020. Aging, Male Sex, Obesity, and Metabolic Inflammation Create

the Perfect Storm for COVID-19. *Diabetes* **69**:1857–1863.

McCarville JL, Ayres JS. 2018. Disease tolerance: concept and mechanisms. *Curr Opin*

Immunol **50**:88–93.

Medzhitov R, Schneider DS, Soares MP. 2012. Disease tolerance as a defense strategy.

Science **335**:936–941.

Monticelli LA, Osborne LC, Noti M, Tran SV, Zaiss DMW, Artis D. 2015. IL-33 promotes

an innate immune pathway of intestinal tissue protection dependent on

amphiregulin–EGFR interactions. *Proc Natl Acad Sci U S A* **112**:10762–10767.

Monticelli LA, Sonnenberg GF, Abt MC, Alenghat T, Ziegler CGK, Doering TA,

Angelosanto JM, Laidlaw BJ, Yang CY, Sathaliyawala T, Kubota M, Turner D,

Diamond JM, Goldrath AW, Farber DL, Collman RG, Wherry EJ, Artis D. 2011.

Innate lymphoid cells promote lung-tissue homeostasis after infection with

influenza virus. *Nat Immunol* **12**:1045–1054.

Mudd PA, Crawford JC, Turner JS, Souquette A, Reynolds D, Bender D, Bosanquet JP,

Anand NJ, Striker DA, Martin RS, Boon ACM, House SL, Remy KE, Hotchkiss RS,

Presti RM, O'Halloran JA, Powderly WG, Thomas PG, Ellebedy AH. 2020. Distinct

inflammatory profiles distinguish COVID-19 from influenza with limited

contributions from cytokine storm. *Sci Adv* **6**. doi:10.1126/sciadv.abe3024

O'Driscoll M, Ribeiro Dos Santos G, Wang L, Cummings DAT, Azman AS, Paireau J,

Fontanet A, Cauchemez S, Salje H. 2020. Age-specific mortality and immunity

patterns of SARS-CoV-2. *Nature*. doi:10.1038/s41586-020-2918-0

Patin E, Hasan M, Bergstedt J, Rouilly V, Libri V, Urrutia A, Alanio C, Scepanovic P,

Hammer C, Jönsson F, Beitz B, Quach H, Lim YW, Hunkapiller J, Zepeda M,

Green C, Piasecka B, Leloup C, Rogge L, Huetz F, Peguillet I, Lantz O, Fontes M,

Di Santo JP, Thomas S, Fellay J, Duffy D, Quintana-Murci L, Albert ML, Milieu

Intérieur Consortium. 2018. Natural variation in the parameters of innate immune

cells is preferentially driven by genetic factors. *Nat Immunol* **19**:302–314.

Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR,

Rosser EC, Webb K, Deakin CT. 2020. Male sex identified by global COVID-19

meta-analysis as a risk factor for death and ITU admission. *Nature*

Communications **11**:6317.

Piasecka B, Duffy D, Urrutia A, Quach H, Patin E, Posseme C, Bergstedt J, Charbit B,

Rouilly V, MacPherson CR, Hasan M, Albaud B, Gentien D, Fellay J, Albert ML,

Quintana-Murci L, Milieu Intérieur Consortium. 2018. Distinctive roles of age, sex,

and genetics in shaping transcriptional variation of human immune responses to

microbial challenges. *Proc Natl Acad Sci U S A* **115**:E488–E497.

Poline J, Gaschignard J, Leblanc C, Madhi F, Foucaud E, Nattes E, Faye A, Bonacorsi

S, Mariani P, Varon E, Smati-Lafarge M, Caseris M, Basmaci R, Lachaume N,

Ouldali N. 2020. Systematic SARS-CoV-2 screening at hospital admission in

children:a French prospective multicenter study. *Clin Infect Dis*.

doi:10.1093/cid/ciaa1044

R Core Team. 2020. R: A Language and Environment for Statistical Computing.

Ra SH, Lim JS, Kim G-U, Kim MJ, Jung J, Kim S-H. 2021. Upper respiratory viral load in

asymptomatic individuals and mildly symptomatic patients with SARS-CoV-2

infection. *Thorax* **76**:61–63.

Råberg L, Sim D, Read AF. 2007. Disentangling genetic variation for resistance and

tolerance to infectious diseases in animals. *Science* **318**:812–814.

Rak GD, Osborne LC, Siracusa MC, Kim BS, Wang K, Bayat A, Artis D, Volk SW. 2016. IL-33-Dependent Group 2 Innate Lymphoid Cells Promote Cutaneous Wound Healing. *J Invest Dermatol* **136**:487–496.

Rauber S, Luber M, Weber S, Maul L, Soare A, Wohlfahrt T, Lin N-Y, Dietel K, Bozec A, Herrmann M, Kaplan MH, Weigmann B, Zaiss MM, Fearon U, Veale DJ, Cañete JD, Distler O, Rivellese F, Pitzalis C, Neurath MF, McKenzie ANJ, Wirtz S, Schett G, Distler JHW, Ramming A. 2017. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. *Nat Med* **23**:938–944.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP. 2020. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. *JAMA* **323**:2052–2059.

Riphagen S, Gomez X, Gonzalez-Martinez C, Wilkinson N, Theocharis P. 2020. Hyperinflammatory shock in children during COVID-19 pandemic. *Lancet*.

Sanchez KK, Chen GY, Schieber AMP, Redford SE, Shokhirev MN, Leblanc M, Lee YM, Ayres JS. 2018. Cooperative Metabolic Adaptations in the Host Can Favor Asymptomatic Infection and Select for Attenuated Virulence in an Enteric Pathogen. *Cell* **175**:146-158.e15.

Sancho-Shimizu V, Brodin P, Cobat A, Biggs CM, Toubiana J, Lucas CL, Henrickson SE, Belot A, MIS-C@CHGE, Tangye SG, Milner JD, Levin M, Abel L, Bogunovic D,

Casanova J-L, Zhang S-Y. 2021. SARS-CoV-2–related MIS-C: A key to the viral and genetic causes of Kawasaki disease? *J Exp Med* **218**. doi:10.1084/jem.20210446

Schneider DS, Ayres JS. 2008. Two ways to survive infection: what resistance and tolerance can teach us about treating infectious diseases. *Nature Reviews Immunology* **8**:889–895.

Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. 2020. Considering how biological sex impacts immune responses and COVID-19 outcomes. *Nat Rev Immunol* **20**:442–447.

Solana R, Tarazona R, Gayoso I, Lesur O, Dupuis G, Fulop T. 2012. Innate immunosenescence: effect of aging on cells and receptors of the innate immune system in humans. *Semin Immunol* **24**:331–341.

Tesoriero JM, Swain C-AE, Pierce JL, Zamboni L, Wu M, Holtgrave DR, Gonzalez CJ, Udo T, Morne JE, Hart-Malloy R, Rajulu DT, Leung S-YJ, Rosenberg ES. 2021. COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. *JAMA Netw Open* **4**:e2037069.

Verdoni L, Mazza A, Gervasoni A, Martelli L, Ruggeri M, Ciuffreda M, Bonanomi E, D'Antiga L. 2020. An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study. *Lancet* **395**:1771–1778.

Vivier E, Artis D, Colonna M, Diefenbach A, Di Santo JP, Eberl G, Koyasu S, Locksley RM, McKenzie ANJ, Mebius RE, Powrie F, Spits H. 2018. Innate Lymphoid Cells: 10 Years On. *Cell* **174**:1054–1066.

Wang A, Huen SC, Luan HH, Yu S, Zhang C, Gallezot J-D, Booth CJ, Medzhitov R. 2016.

Opposing Effects of Fasting Metabolism on Tissue Tolerance in Bacterial and Viral

Inflammation. *Cell* **166**:1512-1525.e12.

Wang Y, Lifshitz L, Gellatly K, Vinton CL, Busman-Sahay K, McCauley S, Vangala P, Kim

K, Derr A, Jaiswal S, Kucukural A, McDonel P, Hunt PW, Greenough T, Houghton

J, Somsouk M, Estes JD, Brenchley JM, Garber M, Deeks SG, Luban J. 2020.

HIV-1-induced cytokines deplete homeostatic innate lymphoid cells and expand

TCF7-dependent memory NK cells. *Nat Immunol* **21**:274–286.

Whittaker E, Bamford A, Kenny J, Kaforou M, Jones CE, Shah P, Ramnarayan P, Fraisse

A, Miller O, Davies P, Kucera F, Brierley J, McDougall M, Carter M, Tremoulet A,

Shimizu C, Herberg J, Burns JC, Lyall H, Levin M, PIMS-TS Study Group and

EUCLIDS and PERFORM Consortia. 2020. Clinical Characteristics of 58 Children

With a Pediatric Inflammatory Multisystem Syndrome Temporally Associated With

SARS-CoV-2. *JAMA* **324**:259–269.

Wickham H. 2016. ggplot2: Elegant Graphics for Data Analysis. Springer.

Wickham H, Averick M, Bryan J, Chang W, McGowan L, François R, Grolemund G, Hayes

A, Henry L, Hester J, Kuhn M, Pedersen T, Miller E, Bache S, Müller K, Ooms J,

Robinson D, Seidel D, Spinu V, Takahashi K, Vaughan D, Wilke C, Woo K, Yutani

H. 2019. Welcome to the Tidyverse. *JOSS* **4**:1686.

Yang Q, Monticelli LA, Saenz SA, Chi AW-S, Sonnenberg GF, Tang J, De Obaldia ME,

Bailis W, Bryson JL, Toscano K, Huang J, Haczku A, Pear WS, Artis D, Bhandoola

A. 2013. T cell factor 1 is required for group 2 innate lymphoid cell generation.

Immunity **38**:694–704.

Yang Q, Saldi TK, Gonzales PK, Lasda E, Decker CJ, Tat KL, Fink MR, Hager CR, Davis

JC, Ozeroff CD, Muhlrad D, Clark SK, Fattor WT, Meyerson NR, Paige CL,

Gilchrist AR, Barbachano-Guerrero A, Worden-Sapper ER, Wu SS, Brisson GR,

McQueen MB, Dowell RD, Leinwand L, Parker R, Sawyer SL. 2021. Just 2% of

SARS-CoV-2−positive individuals carry 90% of the virus circulating in

communities. *Proc Natl Acad Sci U S A* **118**. doi:10.1073/pnas.2104547118

Yonker LM, Gilboa T, Ogata AF, Senussi Y, Lazarovits R, Boribong BP, Bartsch YC,

Loiselle M, Noval Rivas M, Porritt RA, Lima R, Davis JP, Farkas EJ, Burns MD,

Young N, Mahajan VS, Hajizadeh S, Herrera Lopez XI, Kreuzer J, Morris R,

Martinez EE, Han I, Griswold K Jr, Barry NC, Thompson DB, Church G, Edlow AG,

Haas W, Pillai S, Arditi M, Alter G, Walt DR, Fasano A. 2021. Multisystem

inflammatory syndrome in children is driven by zonulin-dependent loss of gut

mucosal barrier. *J Clin Invest*. doi:10.1172/JCI149633

Yonker LM, Neilan AM, Bartsch Y, Patel AB, Regan J, Arya P, Gootkind E, Park G,

Hardcastle M, St John A, Appleman L, Chiu ML, Fialkowski A, De la Flor D, Lima

R, Bordt EA, Yockey LJ, D'Avino P, Fischinger S, Shui JE, Lerou PH, Bonventre

JV, Yu XG, Ryan ET, Bassett IV, Irimia D, Edlow AG, Alter G, Li JZ, Fasano A.

2020. Pediatric Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-

2): Clinical Presentation, Infectivity, and Immune Responses. *J Pediatr* **227**:45-

52.e5.

Yu G, Wang L-G, Han Y, He Q-Y. 2012. clusterProfiler: an R Package for Comparing

Biological Themes Among Gene Clusters. *OMICS* **16**:284–287.

Yudanin NA, Schmitz F, Flamar A-L, Thome JJC, Tait Wojno E, Moeller JB, Schirmer M,

Latorre IJ, Xavier RJ, Farber DL, Monticelli LA, Artis D. 2019. Spatial and Temporal

Mapping of Human Innate Lymphoid Cells Reveals Elements of Tissue Specificity.

Immunity **50**:505-519.e4.

Yukselen O, Turkyilmaz O, Ozturk AR, Garber M, Kucukural A. 2020. DolphinNext: a

distributed data processing platform for high throughput genomics. *BMC*

Genomics **21**:310.

Zhang Z-L, Hou Y-L, Li D-T, Li F-Z. 2020. Laboratory findings of COVID-19: a systematic

review and meta-analysis. *Scand J Clin Lab Invest* **80**:441–447.

Zhao Q, Meng M, Kumar R, Wu Y, Huang J, Deng Y, Weng Z, Yang L. 2020.

Lymphopenia is associated with severe coronavirus disease 2019 (COVID-19)

infections: A systemic review and meta-analysis. *Int J Infect Dis* **96**:131–135.

Zheng M, Gao Y, Wang G, Song G, Liu S, Sun D, Xu Y, Tian Z. 2020. Functional

exhaustion of antiviral lymphocytes in COVID-19 patients. *Cell Mol Immunol*.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X, Guan L, Wei

Y, Li H, Wu X, Xu J, Tu S, Zhang Y, Chen H, Cao B. 2020. Clinical course and risk

factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a

retrospective cohort study. *Lancet* **395**:1054–1062.

1203

1204

1205

1206

1207

ACKNOWLEDGEMENTS

We thank the Massachusetts Consortium for Pathogen Readiness Specimen Collection and Processing Team listed below and members of the Yu and Luban Labs. This work was supported in part by the Massachusetts Consortium for Pathogen Readiness through grants from the Evergrande Fund and NIH grants R37AI147868 and R01AI148784 to J.L. and Ruth L. Kirschstein NRSA Fellowship F30HD100110 to N.J.S. The MGH/MassCPR COVID biorepository was supported by a gift from Ms. Enid Schwartz, by the Mark and Lisa Schwartz Foundation, the Massachusetts Consortium for Pathogen Readiness, and the Ragon Institute of MGH, MIT and Harvard. The Pediatric COVID-19 Biorepository was supported by the National Heart, Lung, and Blood Institute (5K08HL143183 to LMY), and the Department of Pediatrics at Massachusetts General Hospital *for* Children (to LMY).

MGH COVID-19 Collection & Processing Team participants Collection Team:

Kendall Lavin-Parsons[1], Blair Parry[1], Brendan Lilley[1], Carl Lodenstein[1], Brenna McKaig[1], Nicole Charland[1], Hargun Khanna[1], Justin Margolin[1]

Processing Team: Anna Gonye[2], Irena Gushterova[2], Tom Lasalle[2], Nihaarika Sharma[2], Brian C. Russo[3], Maricarmen Rojas-Lopez[3], Moshe Sade-Feldman[4], Kasidet Manakongtreecheep[4], Jessica Tantivit[4], Molly Fisher Thomas[4]

Massachusetts Consortium on Pathogen Readiness: Betelihem A. Abayneh[5], Patrick Allen[5], Diane Antille[5], Katrina Armstrong[5], Siobhan Boyce[5], Joan Braley[5], Karen Branch[5], Katherine Broderick[5], Julia Carney[5], Andrew Chan[5], Susan Davidson[5], Michael Dougan[5], David Drew[5], Ashley Elliman[5], Keith Flaherty[5], Jeanne Flannery[5], Pamela Forde[5], Elise Gettings[5], Amanda Griffin[5], Sheila Grimmel[5], Kathleen Grinke[5], Kathryn Hall[5], Meg

Healy[5], Deborah Henault[5], Grace Holland[5], Chantal Kayitesi[5], Vlasta LaValle[5], Yuting Lu[5], Sarah Luthern[5], Jordan Marchewka (Schneider)[5], Brittani Martino[5], Roseann McNamara[5], Christian Nambu[5], Susan Nelson[5], Marjorie Noone[5], Christine Ommerborn[5], Lois Chris Pacheco[5], Nicole Phan[5], Falisha A. Porto[5], Edward Ryan[5], Kathleen Selleck[5], Sue Slaughenhaupt[5], Kimberly Smith Sheppard[5], Elizabeth Suschana[5], Vivine Wilson[5], Galit Alter[6], Alejandro Balazs[6], Julia Bals[6], Max Barbash[6], Yannic Bartsch[6], Julie Boucau[6], Josh Chevalier[6], Fatema Chowdhury[6], Kevin Einkauf[6], Jon Fallon[6], Liz Fedirko[6], Kelsey Finn[6], Pilar Garcia-Broncano[6], Ciputra Hartana[6], Chenyang Jiang[6], Paulina Kaplonek[6], Marshall Karpell[6], Evan C. Lam[6], Kristina Lefteri[6], Xiaodong Lian[6], Mathias Lichterfeld[6], Daniel Lingwood[6], Hang Liu[6], Jinqing Liu[6], Natasha Ly[6], Ashlin Michell[6], Ilan Millstrom[6], Noah Miranda[6], Claire O'Callaghan[6], Matthew Osborn[6], Shiv Pillai[6], Yelizaveta Rassadkina[6], Alexandra Reissis[6], Francis Ruzicka[6], Kyra Seiger[6], Libera Sessa[6], Christianne Sharr[6], Sally Shin[6], Nishant Singh[6], Weiwei Sun[6], Xiaoming Sun[6], Hannah Ticheli[6], Alicja Trocha-Piechocka[6], Daniel Worrall[6], Alex Zhu[6], George Daley[7], David Golan[7], Howard Heller[7], Arlene Sharpe[7], Nikolaus Jilg[8], Alex Rosenthal[8], Colline Wong[8]

[1]Department of Emergency Medicine, Massachusetts General Hospital, Boston, MA, USA.

[2]Massachusetts General Hospital Cancer Center, Boston, MA, USA.

[3]Division of Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA, USA.

[4]Massachusetts General Hospital Center for Immunology and Inflammatory Diseases, Boston, MA, USA.

1254   [5]Massachusetts General Hospital, Boston, MA, USA.

1255   [6]Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA.

1256   [7]Harvard Medical School, Boston, MA, USA.

1257   [8]Brigham and Women's Hospital, Boston, MA, USA.

1258

Author information

1260   Correspondence and requests for materials should be addressed to J.L.

1261   (jeremy.luban@umassmed.edu).